更新于：2024-12-14
Piperacillin Sodium/Sulbactam sodium
哌拉西林钠舒巴坦钠
更新于：2024-12-14
概要
基本信息
药物类型 小分子化药 |
别名 Piperacillin Sodium and Sulbactam sodium、Piperacillin Sodium and Sulbactam Sodium (2:1)、Piperacillin Sodium and Sulbactam Sodium (4:1) + [7] |
作用机制 β-lactamase抑制剂(β-内酰胺酶抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-07-13), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C23H27N5NaO7S |
InChIKeyHKKJNUJNRAREQR-IDYPWDAWSA-N |
CAS号59703-84-3 |
查看全部结构式(2)
关联
2
项与 哌拉西林钠舒巴坦钠 相关的临床试验Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients
A Open Multi-center Clinical Study on Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
100 项与 哌拉西林钠舒巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 哌拉西林钠舒巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 哌拉西林钠舒巴坦钠 相关的专利（医药）
登录后查看更多信息
4
项与 哌拉西林钠舒巴坦钠 相关的文献（医药）2017-12-01Medicine4区 · 医学
A Klebsiella pneumoniae liver abscess presenting with myasthenia and tea-colored urine
4区 · 医学
ReviewOA
作者: Li, Wei ; Xue, Qian ; Jia, Rong ; Miao, Yide ; Liu, Jie ; Wang, Jingtong ; Deng, Lihua
RATIONALE:
Rhabdomyolysis is a well-known syndrome in clinical practice, although rhabdomyolysis caused by a liver abscess is rarely reported and the patient may lack symptoms that are associated with a primary site of infection. Early recognition of this possibility is needed to avoid diagnostic delay and facilitate treatment. We report the case of a 71-year-old woman with a Klebsiella pneumoniae (KP) pyogenic liver abscess who presented with myasthenia and tea-colored urine and also review the 77 reported cases of bacterial rhabdomyolysis.
PATIENT CONCERNS:
The patient was 71 years old and presenting with a 7-day history of myasthenia and a 3-day history of tea-colored urine, but without fever or abdominal pain.
DIAGNOSES:
Laboratory testing in our case revealed rhabdomyolysis, and blood culture revealed KP. Abdominal ultrasonography revealed a hypoechoic enclosed mass, and computed tomography (CT) revealed an enclosed low-density mass (8.3 × 6.6 × 6.1 cm). The main diagnoses were a pyogenic liver abscess with rhabdomyolysis.
INTERVENTIONS:
Empirically intravenous piperacillin-sulbactam and intravenous potassium treatment, as well as fluid infusions and other supportive treatments were provided after admission. After the diagnosis was confirmed and susceptibility test results were available, we adjusted the antibiotics to cefoperazone and sulbactam, which were maintained for 6 weeks.
OUTCOMES:
The patient's symptoms relieved and the abnormal laboratory parameters corrected. Follow-up abdominal ultrasonography at 24 months after her discharge revealed that the abscess had disappeared.
LESSONS:
Early recognition and careful consideration of the underlying cause of rhabdomyolysis are critical to improving the patient's prognosis. Thus, physicians should carefully consider the underlying cause in elderly patients who present with rhabdomyolysis, as they may lack symptoms of a primary infection.
2016-08-01Medicine4区 · 医学
Occurrence of infective endocarditis following endoscopic variceal ligation therapy
4区 · 医学
ArticleOA
作者: Dong, Huihui ; Xv, Lichen ; Li, Lanjuan ; Liu, Xiaoli ; Zhang, Xuan ; Yang, Meifang
BACKGROUND:
Endoscopic variceal ligation (EVL) is the endoscopic treatment of acute esophageal variceal hemorrhage, however, prophylaxis antibiotic during EVL is controversial.
METHODS:
We reported a 60-year-old man with diabetes, liver cirrhosis and hepatocellular carcinoma who received EVL for esophageal variceal haemorrhage.
RESULTS:
On the second day after EVL, the patient developed fever and chills. A week after EVL, the blood cultures were viridans streptococcus positive, and echocardiogram showed a vegetation on the cardiac valve. The patient was therefore diagnosed with infective endocarditis (IE). The patient was cured after 7 weeks of intravenous piperacillin sulbactam sodium. No complications were observed during the 3-month follow-up after discharge.
CONCLUSION:
To our knowledge, this is the first documented case to report IE caused by viridans streptococcus after EVL. Therefore, whether prophylaxis antibiotic should be administered to cirrhotic patients receiving EVL is worth further research.
2010-12-01Zhonghua nei ke za zhi
[In vitro antimicrobial activity of piperacillin-sulbactam and other 7 antimicrobial agents against non-fermentative bacilli].
Article
作者: Zhong, Nan-shan ; Xiao, Shu-nian ; Qiu, Gui-xia ; Zhuo, Chao
OBJECTIVE:
To evaluate the in vitro antimicrobial activity of piperacillin-sulbactam against clinical isolates of non-fermentative bacilli isolated from common infections.
METHODS:
Microdilution was employed to study the antimicrobial resistance.
RESULTS:
A total of 770 strains were collected from 6 hospitals in Guangzhou, including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, Burkholderia cepacia, Flavobacterium, and Alcaligenes. Compared with other β-lactams, piperacillin-sulbactam displayed the highest activity against all the isolates of P.aeruginosa, especially for imipenem non-sensitive isolates, with the susceptibility of 71.9% and 55.8%, respectively. Piperacillin-sulbactam and cefoperazone-sulbactam kept good activity against imipenem sensitive isolates of A.baumannii, with the susceptibility of 71.0% and 73.0%, respectively. For the strains of Burkholderia cepacia, 69% strains exhibited minimal inhibitory concentration (MIC) of ≤ 16 mg/L for piperacillin-sulbactam. For the strains of Flavobacterium, and Alcaligenes, piperacillin-sulbactam also had excellent activity, with the susceptibility of 70.2% and 94.4%, respectively.
CONCLUSION:
Piperacillin-sulbactam exhibits good activity again non-fermentative bacilli, especially for imipenem non-sensitive isolates of P.aeruginosa.
100 项与 哌拉西林钠舒巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 中国 | 2005-07-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用